A review of the efficacy and safety of fluticasone propionate/formoterol fixed-dose combination.

Introduction: Fluticasone propionate/formoterol fumarate (FP/FORM) is one of the newer combinations among inhaled corticosteroid (ICS) and long-acting β2-agonist (LABA) combination formulations currently available. To evaluate the efficacy and safety of this FP/FORM combination, it is important to review all the available evidence and take a comprehensive look at the current and relevant data in the patient population suffering from asthma and chronic obstructive pulmonary disease (COPD).

Areas Covered: In this focused review, we summarize the available literature published until January 2021 using the PubMed/Medline and Cochrane Controlled Trials Register databases on the efficacy and safety of FP/FORM with its mono-components; concurrent administration of FP+FORM; and with other ICS/LABA combinations in asthma and COPD patients.

Comparison of fluticasone/formoterol with budesonide/formoterol pMDI in adults with moderate to severe persistent asthma: Results from a 12-week randomized controlled trial.

Background: Combination therapy of inhaled corticosteroid/long acting β-agonist (ICS/LABA) is the cornerstone of managing asthmatics who are uncontrolled with low-medium dose of ICS. The novel ICS/LABA combination of fluticasone propionate and formoterol (flu/form) provides potent anti-inflammatory and rapid bronchodilatory effect. This randomized, multi-centre, double-blind study compared the efficacy and safety of flu/form (125/6 mcg BD; Maxiflo) with the well-established budesonide/formoterol combination (bud/form 200/6 mcg BD), both delivered through a pressurized metered dose inhaler (pMDI) in patients with moderate to severe persistent asthma over 12 weeks.

Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review.

Objective: Micronized fenofibrate prevents the progression of microvascular complications in type 2 diabetes, but no systematic review has summarized these effects. Therefore, we performed a systematic review to investigate the effects of micronized fenofibrate on type 2 diabetes-related microvascular complications.

Research Design And Methods: The PubMed database was systematically searched for trials in English language published between January 1990 and November 2015 that examined the effects of fenofibrate on microvascular complications in patients with type 2 diabetes.

A randomized, double-blind study comparing the efficacy and safety of a combination of formoterol and ciclesonide with ciclesonide alone in asthma subjects with moderate-to-severe airflow limitation.

Context: The combination of inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) is widely used in the treatment of moderate-to-severe asthma uncontrolled by ICS alone.

Aims: To evaluate the efficacy and safety of a new ICS-LABA combination inhaler containing Formoterol (F) and Ciclesonide (C).

Settings And Design: A double-blind, double-dummy, parallel group fashion, multi-centric study.

Ease-of-use, preference, confidence, and satisfaction with Revolizer(®), a novel dry powder inhaler, in an Indian population.

Context: While prescribing an inhaler device, it is important to take into account the usability, preference, confidence, and satisfaction of the patients.

Aims: The present study assessed these parameters with Revolizer(®), a novel dry powder inhaler (DPI), in patients with obstructive airway diseases and in device-naïve healthy participants.

Settings And Design: In this open-label, prospective, multicentre study with 100 participants [n = 50 healthy participants, n = 45 mild asthma patients, and n = 5 mild chronic obstructive pulmonary disease (COPD) patients], all participants were instructed and trained on the use of Revolizer and then the participants subsequently demonstrated the inhalation technique at two visits.

Reformulation of existing antiretroviral drugs.

Purpose Of Review: In the last decade, there has been marked progress in the treatment of HIV/AIDS. Today, nearly 10 million people are receiving ART. Yet, there are several opportunities for the enhancement of current antiretroviral (ARV) drugs by developing new formulations, which could increase bioavailability, reduce pharmacokinetic variability, and reduce the total daily dose.

Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection.

Purpose: Colistin, which had not been used widely because of nephrotoxicity and neurotoxicity, has gained clinical importance in recent times due to the resurgence of multidrug-resistant Gram-negative bacilli. Very few studies, especially pharmacokinetic studies, have been performed with intravenous colistimethate sodium, and none in India. The aim of our study was to study the single-dose and steady-state pharmacokinetics of colistin in patients with multidrug-resistant Gram-negative bacilli infections.

The impact of generic antiviral drugs.

The HIV/AIDS epidemic has spread worldwide, with approximately 40 million people who were infected by the end of 2006. Antiretroviral therapy (ART) has proven to be lifesaving, and can convert AIDS into a chronic but manageable disease. Until a few years ago, the annual cost of treating one patient with HIV/AIDS was between US $10,000 and $12,000--beyond the affordability of most individuals.